Danaher's diagnostics platform generates approximately $8 billion in IVD revenues in 2025, comprising Beckman Coulter Diagnostics in clinical chemistry and immunoassay, Cepheid in molecular diagnostics, Radiometer in critical care and blood gas testing, and Leica Biosystems in anatomic pathology and digital pathology. Cepheid's GeneXpert platform — with over 50,000 installed instruments across more than 180 countries — is the global leader in near-patient molecular testing for tuberculosis, HIV, hepatitis, and infectious disease syndromic panels. Beckman Coulter's DxC series competes directly with Roche cobas, Abbott Alinity, and Siemens Atellica for core laboratory consolidation. Leica Biosystems positions Danaher at the forefront of computational pathology.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — GeneXpert Expansion, Core Lab Consolidation, and Digital Pathology Through 2030
• Financial Performance — Revenue, Revenue by Business Unit, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — GeneXpert, DxC, Radiometer AQT, and Leica Digital Pathology
• Latest Products and Services — Platform Launches, Menu Expansions, and Innovation Pipeline
• M&A — Acquisitions, Divestitures, and Partnerships 2023-2025
• Marketing Tactics — Multi-Brand Strategy, Reagent Rental, and Channel Management
• Organization and Management — Leadership, Structure, and Workforce
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most significant developments 2024-2025
- Strategic recommendations
2. Strategic Directions
- Portfolio strategy and capital allocation priorities
- Technology investment focus areas
- Geographic expansion and market development
- Growth priorities through 2030
3. Financial Performance
- Revenue and revenue growth 2023-2025
- Revenue by segment 2023-2025
- Revenue by geography 2023-2025
- Operating income, margins, and EBITDA 2023-2025
- R&D investment 2023-2025
4. SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
5. Technological Know-How
- Core technology capabilities and IP portfolio
- AI and digital diagnostics investments
- Key platform systems and technology milestones
6. Latest Products and Services
- Recent product and platform launches 2023-2025
- Key analyzer and reagent portfolio
- Innovation pipeline and development programs
7. M&A
- Acquisitions, divestitures, and partnerships 2023-2025
8. Marketing Tactics
- Segment and channel positioning
- Reagent rental and placement strategy
- Key account and GPO strategy
9. Organization and Management
- Leadership and executive team
- Organizational structure and key changes
- Workforce size and developments
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. Danaher Diagnostics — Key Financial Metrics Summary 2023-2025
Table 2. Danaher Diagnostics — Revenue by Segment 2023-2025
Table 3. Danaher Diagnostics — Revenue by Geography 2023-2025
Table 4. Danaher Diagnostics — R&D Investment 2023-2025
Table 5. Danaher Diagnostics — SWOT Analysis
Table 6. Danaher Diagnostics — Core Technology Capabilities and Key Platforms
Table 7. Danaher Diagnostics — Key Analyzers and Reagent Portfolio
Table 8. Danaher Diagnostics — M&A Activity Summary 2023-2025
Table 9. Danaher Diagnostics — Key Management and Leadership
Table 10. Danaher Diagnostics — Strategic Priorities 2025-2030
Danaher (Beckman Coulter, Cepheid, Radiometer)
